NCT00794716View on ClinicalTrials.gov

PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

November 30, 2011

Conditions
Non-Alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
Interventions
DRUG

NRL972

Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Norgine
All Listed Sponsors
lead

Norgine

INDUSTRY